---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-26-104317"
form_type: "8-K"
ticker: "ALLR"
cik: "0001860657"
company_name: "Allarity Therapeutics, Inc."
filed_at: "2026-09-29T12:00:30+00:00"
generated_at: "2026-10-12T13:42:16.407351+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.2
calibrated_materiality_score: 0.2
confidence: "high"
source: SEC EDGAR
---

# Allarity expands in-house lab to proteomics and cell line research, citing no cash-runway impact

## Summary
- In-house medical laboratory adds proteomics and cell line research, building on existing transcriptomics work and CLIA clinical testing services.
- nCounter Pro instrument now also runs the nCounter Human Tumor Signaling Protein Panel, which measures approximately 300 protein targets.
- Company says the expansion will not affect its current cash runway and may generate cost efficiencies by enabling more research in-house.
- CEO Thomas Jensen: broader molecular insights support stenoparib (2X-121), a dual PARP and WNT pathway inhibitor in Phase 2 development.
- New capabilities broaden the research services Allarity can offer to existing and prospective external partners.

## SEC filing metadata
- accession: 0001213900-26-104317
- form_type: 8-K
- ticker: ALLR
- cik: 0001860657
- company_name: Allarity Therapeutics, Inc.
- filed_at: 2026-09-29T12:00:30+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.2
- calibrated_materiality_score: 0.2
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1860657/000121390026104317/0001213900-26-104317-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1860657/000121390026104317/ea0306873-8k_allarity.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-26-104317
- JSON: https://secwatch.observer/filing/0001213900-26-104317.json
- Plain text: https://secwatch.observer/filing/0001213900-26-104317.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.